Company Profile
Adlai Nortye Ltd. Stock Price, News & Analysis
- Ticker:
- ANL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
13.84 USD (+5.89%)
Close
Last updated: August 6, 2026
746M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ANL closed up 5.89% at $13.84. No new same-company headline was identified in the current news window.
Company overview
Business overview
Annovis Bio is a biotechnology company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its story centers on trying to address difficult CNS diseases with a focused molecular approach.
Geographic Base and Sector Classification
Annovis is headquartered in the United States and listed on NASDAQ. It sits in neuroscience biotechnology.
Business Model Characteristics
The company depends on clinical proof, translational confidence, and the ability to keep a narrow pipeline funded. Investors usually watch early data and whether the biology can support a meaningful CNS thesis.
Position Within the Biotechnology Landscape
Annovis occupies a high-risk neurodegeneration niche within biotech. The stock is highly dependent on whether the company can show a real disease-modifying effect.
Future catalysts
Adlai Nortye’s catalysts are its oncology pipeline and any clinical update that clarifies whether the company can still build a meaningful development story. The stock remains early and data-dependent.
Recent news
- 01
- 02
- 03
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
Source: Adlai Nortye Ltd.
- 04
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
Source: Adlai Nortye Ltd.
- 05
Adlai Nortye to Participate in Upcoming Investor Conferences
Source: Adlai Nortye Ltd.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Adlai Nortye Ltd. (ANL)?
Adlai Nortye Ltd. (ANL) most recently closed at 13.84 USD, a +5.89% move versus the previous session.
What is the market cap of Adlai Nortye Ltd. (ANL)?
Adlai Nortye Ltd. currently has a market capitalization of 746M USD on BioPharmSignal.
What does Adlai Nortye Ltd. do?
Annovis Bio is a biotechnology company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its story centers on trying to address difficult CNS diseases with a focused molecular approach.
On which exchange is ANL stock listed?
Adlai Nortye Ltd. (ANL) is associated with NASDAQ, United States, Biopharma.
What is Annovis?
Annovis Bio is a biotechnology company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
Which conditions is Adlai Nortye Ltd. targeting with Annovis?
Adlai Nortye Ltd. is associated with oncology based on its company overview and current catalyst commentary.
How does Adlai Nortye Ltd. describe recent progress with Annovis?
Adlai Nortye’s catalysts are its oncology pipeline and any clinical update that clarifies whether the company can still build a meaningful development story. The stock remains early and data-dependent.
What is Alzheimer?
Annovis Bio is a biotechnology company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s.